AiCure

Drug Sponsors

SRI International opens clinical trial unit in Michigan

Monday, October 27, 2014 01:04 PM

SRI Biosciences, a division of SRI International, a California-based independent nonprofit research institute, has completed construction of an early-phase clinical trial facility in Plymouth, Mich. The 9,400-square-foot unit, located in the Michigan Life Science Innovation Center, now is open and fully equipped for early-stage human research studies of new medicines and medical devices. 

More... »


Report: 10 men for every woman present in biotech boardrooms

Monday, October 27, 2014 12:57 PM

The biotechnology sector is considerably under represented by female executives and board directors, according to a new report by Liftstream, a U.K.-based company providing executive recruitment services to the biotechnology sector. The gender diversity report, Diversifying the Outlook—The X&Y of Biotechnology Leadership, is a detailed analysis of women leaders in European and U.S. biotech companies.

More... »

CenterWatch

Lilly, Zymeworks expand collaboration agreement

Friday, October 24, 2014 01:10 PM

Eli Lilly and Zymeworks, a Vancouver-based, privately held biotherapeutics company, are expanding an existing licensing and collaboration agreement. Originally announced in January, the global strategic collaboration is focused on the development of an undisclosed number of novel bi-specific antibody therapeutics using Zymeworks' proprietary Azymetric platform.

More... »

Celgene collaborates with Sutro Biopharma, inks option to acquire

Friday, October 24, 2014 01:09 PM

Sutro Biopharma, located in South San Francisco, has entered into a strategic collaboration and option agreement with Celgene to discover and develop multispecific antibodies and antibody drug conjugates (ADCs). This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development and manufacture of best-in-class biotherapeutics.

More... »

J&J Innovation adds J-Labs incubator at Texas Medical Center

Friday, October 24, 2014 01:07 PM

Johnson & Johnson Innovation plans to expand J-Labs (formerly Janssen Labs) to include a new incubator located within Texas Medical Center's new Innovation Institute. The 30,000-square-foot J-Labs facility will accommodate up to 50 life science startups.

More... »

Treasury’s tax inversion changes scuttle some big biopharma mergers, modify others, prompting calls for Congressional corporate tax reform

Thursday, October 23, 2014 03:50 PM

By Ronald Rosenberg
CenterWatch Staff Writer

The widely-discussed $54.6 billion acquisition of Dublin-based Shire by AbbVie is officially canceled, having crumbled after a notice by the U.S. Treasury Department to tighten tax rules that deter U.S. companies from moving their legal headquarters to countries with lower business taxes.

More... »

Roche invests in its Switzerland site

Thursday, October 23, 2014 01:23 PM

Roche has presented development plans for its Basel, Switzerland site. Over the next 10 years, Roche will invest $3.1 billion in the construction of a new R&D center for around 1,900 employees, a state-of-the-art office building for up to 1,700 employees.

More... »

Actavis signs option to acquire Rhythm subsidiary

Thursday, October 23, 2014 01:08 PM

Actavis, a Dublin, Ireland-based global specialty pharmaceutical company, has been granted an exclusive option to acquire Rhythm subsidiary Rhythm Health, a Boston, Mass.-based biopharmaceutical company developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other GI functional disorders.

More... »

Fidelity Biosciences and Atlas Venture launch Unum Therapeutics

Wednesday, October 22, 2014 11:28 AM

Fidelity Biosciences and Atlas Venture, with participation from Sanofi-Genzyme BioVentures, have launched Unum Therapeutics, a company developing cellular immunotherapy to treat cancer. Fidelity Biosciences invests venture capital in biopharmaceutical, medical technology, healthcare information technology and healthcare service companies, while Atlas Venture is an early-stage investor. All three are based in Cambridge, Mass.

More... »

Bone Biologics completes merger with AFH Acquisition X

Friday, October 17, 2014 12:34 PM

Bone Biologics, a California-based company developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or Nell-1) for use with patients undergoing spinal fusion, has completed a reverse merger with AFH Acquisition X, a fully-reporting company with the Securities and Exchange Commission. The combined company changed its name to Bone Biologics.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs